Summary
Therapy for Gram-negative sepsis remains unsatisfactory despite a concerted effort to develop new treatments for this common, life-threatening syndrome. Current research continues on several fronts to improve the treatment options available to clinicians in the management of these critically ill patients. Recently, a greater understanding of the complex molecular basis of endotoxin-mediated pathophysiological effects in humans has generated a number of novel therapeutic agents for sepsis. Several of these treatment strategies have already entered clinical trials and it is hoped that some of these therapies will become widely available in the near future.
In this review, the current status of the most promising new antiendotoxin agents is summarised, and the major obstacles to the successful clinical development of these therapies are described. New antiendotoxin therapies include those which interrupt the synthesis of endotoxin, bind and neutralise its activity, prevent endotoxin interactions with host effector cells and interfere with endotoxinmediated signal transduction pathways. Potential therapeutic strategies involving these agents consist of endotoxin analogues, antibodies, subunit vaccines, binding columns, recombinant human proteins and small molecule inhibitors of endotoxin synthesis and intracellular signalling. The pitfalls of previous antiendotoxin clinical investigations and the perils of future clinical trial designs are discussed in the context of unmet needs and realistic expectations for success.
While considerable progress has been made, effective and new treatments for Gram-negative bacterial sepsis continues to elude us at the present time. This has been to the detriment of patients, investigators and pharmaceutical companies alike. It will require focused efforts by basic scientists, continued support by industry and enlightened study designs by clinical investigators to successfully develop antiendotoxin therapies for use in septic patients in the future.
Article PDF
Similar content being viewed by others
References
Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical trial of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23: 994–1006
Baumgartner J-D, Glauser M-P, et al. Immunotherapy of endotoxemia and septicemia. Immunobiology 1993; 187: 464–77
Cross AS, Opal SM. Therapeutic intervention in sepsis with antibody to endotoxin: is there a future? J Endotoxin Res 1994; 1: 57–69
Rietschel ET, Kirikae T, Schade FU, et al. Bacterial endotoxin: molecular mechanisms of structure to activity and function. FASEB J 1994; 218: 217–25
Horn DL, Opal SM, Lomastro E. Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in Gram-negative sepsis. Scand J Infect Dis 1996; 101: 9–13
Opal SM. Lessons learned from clinical trials of sepsis. J Endotoxin Res 1995; 2: 1–6
Zeigler EJ, Fisher Jr CJ, Sprung CL, et al. Treatment of gram-negative bacteremia in septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 429–38
Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266: 1097–102
Ulevitch RJ, Dunn DL, Fink MP, et al. Endotoxin-related intracellular pathways: implications for therapeutic intervention. Shock 1996; 6: 1–2
Rietschel ET, Brade H, Holst O, et al. Bacterial endotoxin: chemical composition, biological recognition, host response, and immunological detoxification. Curr Topics Microbiol Immunol 1996; 216: 39–81
Mamat U, Rietschel ET, Schmidt G. Repression of lipopolysaccharide biosynthesis in Escherichia coli by an antisense RNA of Acetobacter methanolicus phage Acml. Mol Microbiol 1995; 15: 1115–25
Galloway SM, Raetz CR. J Bi A mutant of Escherichia coli defective in the first step of endotoxin biosynthesis. Chem 1990; 265(11): 6394–402
Vuorio R, Vaara M. The lipid A biosynthesis mutation of lpxA2 of Escherichia coli results in drastic antibiotic supersusceptibility. Antimicrob Agents Chemother 1992 Apr; 36(4): 826–9
Raetz CR. Bacterial endotoxins: extraordinary lipids that activate eukaryotic signal transduction. J Bacteriol 1993; 175(18): 5745–53
Young K, Silver LL, Bramhill D, et al. The envA permeability/cell division gene of Escherichia coli encodes the second enzyme of lipid A biosynthesis. J Biol Chem 1995 Dec 22; 270(51): 30384–91
Onishi HR, Pelak BA, Gerckens LS, et al. Antibacterial agents that inhibit lipid A biosynthesis. Science 1996; 274: 980–2
Kelly TM, Stachula SA, Raetz CRH, Anderson MS. The flrA gene of Escherichia coli encodes UDP-3-O-(R-3-hydroxy-myristoyl)-glucosamine-N-acyltransferase. J Biol Chem 1993; 268(26): 19866–74
Goldman R, Kohlbrenner W, Lartey P, et al. Antibacterial agents specifically inhibiting lipopolysaccharide synthesis. Nature 1987; 329: 162–4
Hammond SM, Claesson A, Jansson AM, et al. A new class of synthetic antibacterials acting on lipopolysaccharide biosynthesis. Nature 1987; 327: 730–2
Braude AI, Ziegler EJ, Douglas H, et al. Antibody to cell wall glycolipid of gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. J Infect Dis 1977; 136: S167–73
Warren HS, Amato SF, Fitting C, et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 1993; 177: 89–97
Baumgartner J-D, Heumann D, Gerain J, et al. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin-6: comparison of O-side chain specific antibodies with core LPS antibodies. J Exp Med 1990; 171: 889–96
Bhart NM, Bieber MM, Chapman CJ, et al. Human anti-lipid A monoclonal antibodies bind to human B cells and i-antigen on core red blood cells. J Immunol 1993; 151: 5011–21
Quezado ZMM, Natanson C, Ailing DW, et al. A controlled trial of HA-1A in a canine model of gram-negative septic shock. JAMA 1993; 269: 2221–7
Goldie AS, Fearon KCH, Ross JA, et al. Natural cytokine and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 1995; 274: 172–7
Nys M, Damas P, Joassin L, et al. Sequential anti-core glycolipid immunoglobulin antibody activities with and without septic shock and their relation to outcome. Ann Surg 1993; 217: 300–6
DiPadova FE, Barclay R, Brade H, et al. SDZ219-800: a chimeric broadly cross-reactive and cross-neutralizing anti-core LPS antibody [abstract no. 12.3]. Circ Shock 1993; 1 Suppl. 47
Bhattercharjee AK, Opal SM, Taylor R, et al. A non-covalent complex vaccine prepared with detoxified E. coli J5 LPS and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteria. J Infect Dis 1996; 173: 1157–62
Bhattercharjee AK, Opal SM, Palardy JE, et al. Affinity purified E. coli J5 LPS-specific IgG protects neutropenic rats against gram-negative sepsis J Infect Dis 1994; 170: 622–9
Donta ST, Peduzzi P, Cross AS, et al. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. J Infect Dis 1996; 174: 537–43
Ooi CE, Weiss J, Elsbach P. Structural and functional organization of the human neutrophil 60kDa bactericidal/permeability-increasing protein. Agents and Actions 1991; 34: 274–7
Marra MN, Wilde CG, Griffith JE, et al. Bactericidal/permeability-increasing protein has endotoxin-neutralizing ability. J Immunol 1990; 144: 662–6
Elsbach P, Weiss J. Bactericidal/permeability-increasing protein and host defense against gram-negative bacteria in endotoxin. Curr Opin Immunol 1993; 5: 103–7
Marra MN, Wilde CG, Collins MS, et al. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992; 148: 532–7
Gazzano-Santoro H, Meszaros K, Birr C, et al. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun 1994; 62: 1185–91
Schumann RR, Leong SR, Flaggs GW Structure and function of lipopolysaccharide-binding protein. Science 1992; 49: 1431–3
Opal SM, Palardy JE, Marra MN, et al. Relative concentrations of endotoxin-binding proteins in body fluids during infection. Lancet 1994; 344: 429–31
Bermer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 4.5 angstrom resolution. Science 1997; 276: 1861–4
Von der Mohlen MAM, Kimmings AN, Wedel NI, et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans using recombinant bactericidal/permeability-increasing protein (rBPI23). J Infect Dis 1995; 172: 144–51
Giroir B, Carroll S, Scannon P. Phase I/II trial of rBPI21 in children with severe meningococcemia [abstract no. 414]. Infectious Disease Society of America Annual Meeting; Sept 15 1997: San Francisco (CA)
Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995; 181: 1743–54
Flegel WA, Wolpl A, Mannel DA, et al. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57: 2237–45
Levine DM, Parker TS, Donnelly TM, et al. ln-vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90: 12040–4
Pajkrt D, Doran JE, Coster F, et al. Anti-inflammatory affects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601–8
Lerch PG, Fortsch V, Hodler G, et al. Production and characterization of a reconstituted high density lipoprotein (rHDL) for therapeutic application. Vox Sang 1996; 71: 155–64
Kodama M, Tani T, Hanasawa K. Extracorporeal removal of endotoxin in the septic patients by toraymyxin — clinical results in a phase II and III study in Japan [abstract]. Shock 1997; 7 Suppl.: 6
Hanasawa K, Tani T, Kodama M. New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg Gynecol Obstet 1989; 168: 323–31
Weber C, Rajnoch C, Schima H, et al. The microspheres based detoxification system (MDS). Int J Artif Organs 1994; 17(11): 595–602
Lonergan JM, Orlowski JP, Sato T, et al. Extracorporeal endotoxin removal in a canine model of septic shock. ASAIO J 1994; 40: M654–7
Aoki H, Kodama M, Tani T, et al. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994; 167: 412–7
Palmer JD, Rifkind D. Neutralization of the hemodynamic effects of endotoxin by polymyxin B. Surg Gynecol Obstet 1974; 138: 755–9
Cheadle WG, Hanasawa K, Gallinaro RN, et al. Endotoxin filtration and immune stimulation improve survival from gram-negative sepsis. Surgery 1991; 110: 785–92
Sato T, Orlowski JP, Zborowski M. Experimental study of extracorporeal perfusion for septic shock. ASAIO J 1993; 39: M790–3
Kodama M, Tani T, Maekawa K, et al. Endotoxin eliminating therapy in patients with severe sepsis-direct hemoperfusion using polymyxin B immobilized fiber column. J Endotoxin Res. In press
Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Ann Rev Med 1987; 38: 417–32
Lynn WA, Golenbock DT. Lipopolysaccharide antagonists. Immunol Today 1992; 13: 271–6
Krauss JH, Seydel U, Weckesser J, et al. Structural analysis of the nontoxic lipid A of Rhodobacter capsulatus 37b 4. Eur J Biochem 1989; 180: 519–6
Loppnow H, Libby P, Freudenberg MA, et al. Cytokine induction by LPS corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun 1990; 558: 3743–50
Kawata T, Bristol J, Mcguigan L, et al. Anti-endotoxin activities of E5531, a novel synthetic derivative of lipid A [abstract no. 1360]. Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14 Oct 1992: 337
Christ WJ, Osamu A, Robidoux ALC, et al. E5531 a pure endotoxin antagonist of high potency. Science 1995 268: 80–3
Kawata T, Bristol JR, Rose JR, et al. Anti-endotoxin activity of a novel synthetic lipid A analog. Prog Clin Biol Res 1995; 392: 499–509
Crosby HA, Bion JF, Penn CW, et al. Antibiotic-induced release of endotoxin from bacteria in vitro. J Med Microbiol 1994; 40: 23–30
Kawata T, Bristol JR, Rose JR, et al. Specific lipid A analog which exhibits exclusive antagonism of endotoxin. In: Morrison D, Ryan J, editors. Novel therapeutic strategies in the treatment of sepsis. New York: Marcel Dekker, Inc., 1996; 171–86
Ferrero E, Jiao D, Tsuberi BZ, et al. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc Natl Acad Sci USA 1993; 90: 2380–4
Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Ann Rev Immunol 1995; 13: 437–57
Arditi M, Zhou J, Dorio R, et al. Endotoxin-mediated endothelial cell injury and activation: role of soluble CD 14. Infect Immun 1993; 61: 3149–56
Delude RL, Savedra Jr R, Zhao HL. CD14 enhances cellular responses to endotoxin without imparting ligand-specific recognition. Proc Natl Acad Sci USA 92: 9288–92
Kusunoki T, Hailman E, Juan TS-C, et al. Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. J Exp Med 1995; 182: 1673–82
Pugin J, Heumann D, Tomasz A, et al. CD14 as a pattern recognition receptor. Immunity 1994; 1: 509–16
Haziot A, Ferrero E, Kontgen F, et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4: 407–14
McGinley MD, Norhi LO, Kelley MJ, et al. CD14: physical properties and identification of an exposed site that is protected by a lipopolysaccharide. J Biol Chem 1995; 270: 5213–8
Juan TS-C, Hailman E, Kelley MJ, et al. Identification of lipopolysaccharide binding domain in CD14 between amino acids 57 and 64. J Biol Chem 1995; 270: 5219–24
Shapiro RA, Cunningham MD, Ratcliffe K, et al. Identification of CD14 residues involved in specific lipopolysaccharide recognition. Infect Immun 1997; 65: 293–7
Wright SD. CD14 and innate recognition of bacteria. J Immunol 1995; 155: 6–8
Leturcq DG, Moriarty AM, Talbott G, et al. Antibodies against CD 14 protect primates from endotoxin-induced shock. J Clin Invest 1996; 98: 1533–8
Ulevitch RJ, Tobias PS. Recognition of endotoxin by cells leading to transmembrane signalling. Curr Opin Immunol 1994; 6: 125–30
Cordle SR, Donald R, Read MA, et al. Lipopolysaccharide induces phosphorylation of MAD3 and activation of c-REL in related NF-κB proteins in human monocytic THP-1 cells. J Biol Chem 1993; 268: 11803–10
Savransky JE, Schaked G, Novogrodsky A, et al. Tyrphostin AG556 improves survival and reduces multi-organ failure in canine Escherichia coli peritonitis. J Clin Invest 1997; 99: 1966–73
Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25: 1097–100
Fisher Jr CJ, Agosti J, Opal SM, et al. Treatment of septic shock with tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697–702
Opal SM, Cross AS, Jhung J, et al. Potential hazards of combination immunotherapy in the treatment of experimental sepsis. J Infect Dis 1996; 173: 1415–21
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Opal, S.M., Yu, R.L. Antiendotoxin Strategies for the Prevention and Treatment of Septic Shock. Drugs 55, 497–508 (1998). https://doi.org/10.2165/00003495-199855040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199855040-00002